75
Views
14
CrossRef citations to date
0
Altmetric
Review

Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study

, , &
Pages 467-479 | Published online: 15 Sep 2007

References

  • AIM-HIGH trial, http://www.clinicaltrials.gov identifier NCT00120289
  • Al-SheikhAAKarasRHRelative safety of lipid altering drugs in the general population2005Abstract 3707, presented at the 2005. American Heart Association Scientific SessionsNov 13–6, 2005Dallas, Texas, USA
  • AssmannGSchulteHvon EckardsteinAHigh-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transportAtherosclerosis1996124Supp lS11208831911
  • BalkauBCharlesMADrivsholmTFrequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndromeDiabetes Metab2002283647612461473
  • BaysHEDujovneCAMcGovernMEComparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])Am J Cardiol2003916677212633795
  • BaysHEMcGovernMEOnce-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatinPrev Cardiol200361798814605511
  • BrownBGZhaoX-QChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med200134515839211757504
  • BrownGAlbersJJFisherLDRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein BN Engl J Med19903231289982215615
  • BruckertEBaccara-DinetMMcCoyFHigh prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patientsCurr Med Res Opin2005a2119273416368042
  • BruckertEPamphileRMcCoyFDefining the prevalence of low HDL-C in a European cohort of dyslipidaemic patientsEuropean Heart J Suppl2005bF236
  • BruckertEBaccara-DinetMEschwegeELow HDL-cholesterol is highly prevalent among European type 2 diabetes patients receiving treatment for dyslipidaemia: data from a pan-European surveyDiabet Med2007In press
  • CannerPLBergeKGWengerNKFifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacinJ Am Coll Cardiol198681245553782631
  • CannerPLFurbergCDTerrinMLBenefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Am J Cardiol200595254715642562
  • CannerPLFurbergCDMcGovernMEBenefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)Am J Cardiol200697477916461040
  • CapuzziDMGuytonJRMorganJMEfficacy and safety of an extended-release niacin (Niaspan): a long-term studyAm J Cardiol19988274U81U
  • Cashin-HemphillLMackWJPogodaJMBeneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-upJAMA1990264301372243429
  • CastelliWPGarrisonRJWilsonPWIncidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham StudyJAMA1986256283583773200
  • CastelliWPCholesterol and lipids in the risk of coronary artery disease—the Framingham Heart StudyCan J Cardiol19884Suppl A5A10A3282627
  • [CDP] Coronary Drug Project Research GroupClofibrate and niacin in coronary heart diseaseJAMA1975231360811088963
  • ChapmanMJHow does nicotinic acid modify the lipid profile?Eur Heart J Suppl20068F549
  • DaltonTABerryRSHepatotoxicity associated with sustained-release niacinAm J Med19929310241626557
  • DominguezLJGaliotoAFerlisiAAgeing lifestyle modifications and cardiovascular disease in developing countriesJ Nutr Health Aging200610143916554951
  • DrexelHAczelSMarteTIs atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?Diabetes Care200528101715616241
  • DubeMPWuJWAbergJASafety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148Antivir Ther2006111081917302378
  • Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA200128524869711368702
  • FordESGilesWHDietzWHPrevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination SurveyJAMA2002287356911790215
  • FrickMHEloOHaapaKHelsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart diseaseN Engl J Med19873171237453313041
  • GoldbergAAlagonaPJrCapuzziDMMultiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemiaAm J Cardiol2000851100510781759
  • GoldbergIJClinical review 124: Diabetic dyslipidemia: causes and consequencesJ Clin Endocrinol Metab2001869657111238470
  • GoldbourtUYaariSMedalieJHIsolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 menArterioscler Thromb Vasc Biol199717107139012644
  • GordonDJProbstfieldJLGarrisonRJHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studiesCirculation1989798152642759
  • GordonTCastelliWPHjortlandMCHigh density lipoprotein as a protective factor against coronary heart disease. The Framingham StudyAm J Med19776270714193398
  • GrundySMVegaGLMcGovernMEEfficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan TrialArch Intern Med200216215687612123399
  • GrundySMVegaGLMcGovernMEComparative effects on lipids and glycemic control of niacin extended-release/lovastatin or fenofibrate in patients with diabetic dyslipidemiaAbstract 29-LB, presented at the 64th Scientific Sessions of the American diabetes AssociationJune 4-8 2004Orlando, Florida, USA
  • GuytonJRCapuzziDMTreatment of hyperlipidemia with combined niacin-statin regimensAm J Cardiol19988282U84U9671014
  • HanselBGiralPNobecourtEMetabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activityJ Clin Endocrinol Metab20048949637115472192
  • HodisHNMackWJLaBreeLThe role of carotid arterial intima-media thickness in predicting clinical coronary eventsAnn Intern Med199812826299471928
  • HunninghakeDBMcGovernMEKorenMA dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatinClin Cardiol200326112812685616
  • InsullWMcGovernMESchrottHEfficacy of extended-release niacin with lovastatin for hypercholesterolemia assessing all reasonable doses with innovative surface graph analysisArch Intern Med20041641121715159270
  • IsomaaBAlmgrenPTuomiTCardiovascular morbidity and mortality associated with the metabolic syndromeDiabetes Care200124683911315831
  • KaneJPMalloyMJPortsTARegression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimensJAMA19902643007122243428
  • KashyapMLMcGovernMEBerraKLong-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemiaAm J Cardiol199889672811897208
  • KasteleinJJPThe realities of dyslipidaemia: what do the studies tell us?Eur Heart J Suppl20057F2733
  • KeechASimesRJBarterPEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet200536618496116310551
  • KnoppRHAlagonaPDavidsonMEquivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemiaMetabolism19984710971049751239
  • McGovernMEMalottCMSimmonsPDOnce-daily niacin-extended-release/lovastatin combination is effective and safe for treatment of dyslipidaemia associated with metabolic syndromeAbstract 820–5 Scientific session of the American College of Cardiology2004
  • McKenneyJMJonesPHBaysHEComparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)Atherosclerosis2007 Epub ahead of print
  • MillerNEHammettFSaltissiSRelationship of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteinsBr Med J1981282174146786600
  • MorganJMCapuzziDMBakshRIEffects of extended-release niacin on lipoprotein subclass distributionAm J Cardiol2003911432612804729
  • MorganJMCapuzziDMGuytonJRTreatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trialJ Cardiovasc Pharmacol Ther1996119520210684417
  • NiskanenLTurpeinenAPenttilaIHyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosisDiabetes Care199821186199802734
  • PieperJAUnderstanding niacin formulationsAm J Manag Care20028Suppl 12S3081412240702
  • PocockSJShaperAGPhillipsANConcentration of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart diseaseBr Med J198929899810022499392
  • RaymondSULeederSGreenbergHMObesity and cardiovascular disease in developing countries: a growing problem and an economic threatCurr Opin Clin Nutr Metab Care20069111616477174
  • RobinsonJGDavidsonMHCombination therapy with ezetimibe and simvastatin to achieve aggressive LDL reductionExpert Rev Cardiovasc Ther200644617616918265
  • RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341410810438259
  • SharrettARBallantyneCMCoadySACoronary heart disease prediction from lipoprotein cholesterol levels triglycerides lipoprotein(a), apolipoproteins A-I and B and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) StudyCirculation200110411081311535564
  • SweetDEMetabolic complications of antiretroviral therapyTop HIV Med20051370416082057
  • TaylorAJLeeHJSullenbergerLEThe effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3Curr Med Res Opin20062222435017076985
  • TaylorAJSullenbergerLELeeHJArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation20041103512715537681
  • Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)European guidelines on cardiovascular disease prevention in clinical practiceEur J Cardiovasc Prev Rehabil200310S1S1014555889
  • TurnerRCMillnsHNeilHARisk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)BMJ199831682389549452
  • VanJTPanJWastyTComparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitusAm J Cardiol2002891306812031735
  • VogtAKassnerUHostalekUEvaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS studyCurr Med Res Opin2006a224172516466614
  • VogtAKassnerUHostalekUNAUTILUS (safety and tolerability of Niaspan®): a subgroup analysis of patients with diabetesBr J Diabetes Vasc Dis2006b612733
  • VogtAKassnerUHostalekUSafety and tolerability of prolonged-release nicotinic acid in patients aged >65 years enrolled in NAUTILUSBr J Cardiol2006c1327882
  • VogtAKassnerUHostalekUSafety and tolerability of prolonged-release nicotinic acid combined with a statin in NAUTILUSBr J Cardiol2006d132737
  • WhitneyEJKrasuskiRAPersoniusBEA randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical eventsAnn Intern Med20051429510415657157
  • WilsonPWAbbottRDCastelliWPHigh density lipoprotein cholesterol and mortality. The Framingham Heart StudyArteriosclerosis19888737413196218
  • WolfeMLVartanianSFRossJLSafety and effectiveness of niaspan when added sequentially to a statin for treatment of dyslipidemiaAm J Cardiol200187476911179541
  • YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet20043649375215364185